Lilly’s Foundayo receives FDA approval to provide needle-free GLP-1 therapy for obesity

USA—Eli Lilly and Company has announced an FDA approval of Foundayo (orforglipron), an oral medication designed for adults struggling with obesity or overweight conditions accompanied by weight-related health problems.

The drug marks a significant addition to the weight management landscape, offering patients a once-daily pill option that requires no special food or water restrictions.

How It Works

When combined with a reduced-calorie diet and regular physical activity, Foundayo helps patients shed excess weight and maintain their progress.

Clinical trials demonstrated that participants receiving the highest dose lost an average of 27.3 pounds (12.4%) compared to just 2.2 pounds (0.9%) for those taking a placebo.

Across the broader trial population, patients lost an average of 25 pounds (11.1%) versus 5.3 pounds (2.1%) with placebo, regardless of whether they completed the full treatment period.

Beyond weight reduction, the medication also improved several cardiovascular risk markers, including waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure across all dosage levels.

Addressing a treatment gap

David A. Ricks, chair and CEO of Eli Lilly, emphasized that fewer than one in ten people who could benefit from GLP-1 medications currently take them.

Barriers including limited access, social stigma, perceived treatment complexity, and patient uncertainty about disease severity have kept many individuals from pursuing weight management options.

Ricks noted that Foundayo addresses these obstacles by providing a practical, convenient solution tailored to real-world patient needs.

Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, reinforced this perspective, noting that many patients benefit from treatment options that integrate seamlessly into their daily routines without imposing lifestyle constraints.

Availability and pricing

Foundayo becomes available immediately through LillyDirect, with shipments beginning April 6.

The medication will subsequently roll out through major U.S. retail pharmacies and telehealth providers.

Eli Lilly has structured pricing to improve accessibility: commercially insured patients may pay as little as USD25 monthly using the Foundayo savings card, while uninsured individuals can access the lowest dose for USD149 per month.

Medicare Part D beneficiaries may qualify for USD 50 monthly pricing beginning July 1, 2026.

Important considerations

Foundayo should not be used alongside other GLP-1 receptor agonist medications, and safety data in children remains unavailable.

The drug carries a potential risk of thyroid tumors, including cancer, requiring patients to monitor for symptoms such as neck lumps, hoarseness, swallowing difficulties, or breathing changes.

Common side effects include nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headaches, fatigue, and hair loss.

Joe Nadglowski, president and CEO of the Obesity Action Coalition, highlighted that expanding treatment options allows individuals to select approaches aligned with their personal circumstances and long-term goals.